Vaccine immunotherapy for immune suppressed patients

Assignee: IRx Therapeutics, Inc.

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,153,499
App. No.: 10/430,506
Granted: Dec 26, 2006
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention provides a formulation for inhibiting metastasis which includes 150–600 units of IL-2, a nonsteroidal anti-inflammatory drug (NSAID), and cyclophosphamide. The present invention further provides a formulation for inhibiting metastasis that includes IL-1, IL-2, IL-6, IL-8, δ-IFN and TNF-α.

Claims (2)

1. A formulation consisting of 150–600 units of IL-2, a non-steroidal anti-inflammatory drug (NSAID) and cyclophosphamide.

2. A formulation consisting of IL-1, IL-2, IL-6, IL-8, IFN-γ and TNF-α.

Assignments (4)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2019

From: IRX THERAPEUTICS, INC.

To: BROOKLYN IMMUNOTHERAPEUTICS LLC

Reel/Frame 048424/0096 →

RELEASE OF SECURITY INTEREST Recorded Dec 13, 2013

From: KOHN & ASSOCIATES PLLC; KOHN, KENNETH I.

To: UNIVERSITY OF SOUTH FLORIDA; IRX THERAPEUTICS, INC.

Reel/Frame 031782/0396 →